肿瘤细胞治疗研究
英文原题：Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.
Mosunetuzumab是一种靶向CD20 x CD3的双特异性抗体，可重新定向T细胞以靶向并摧毁CD20阳性B细胞。
Mosunetuzumab是一种靶向CD20 x CD3的双特异性抗体，可重新定向T细胞以靶向并摧毁CD20阳性B细胞。包括双特异性抗体在内的T细胞疗法已彻底改变了B细胞NHL的治疗。Mosunetuzumab已获批用于至少接受过2线治疗的滤泡性淋巴瘤。NCCN还推荐其用于弥漫性大B细胞淋巴瘤，以及与polatuzumab vedotin联合用于既往接受过BTK抑制剂治疗的复发/难治性套细胞淋巴瘤。已发表的试验显示严重CRS发生率较低，并支持在适当环境下进行门诊给药。通过检索PubMed、会议摘要和clinicaltrials.gov在2020年至2026年间的数据，纳入了前瞻性试验数据以及回顾性真实世界证据和正在进行的研究，以更全面地呈现现有数据。本综述总结了mosunetuzumab的分子设计、作用机制、临床疗效和安全性，该药物是淋巴瘤免疫治疗进展的代表性药物。
Mosunetuzumab is a bispecific antibody targeting CD20 x CD3 re-directing T cells to target and destroy CD20-positive B cells. T-cell-based therapies including bispecific antibodies have revolutionized B-cell NHL treatment. Mosunetuzumab is approved for follicular lymphoma with at least 2 prior lines of therapy. There are also NCCN recommendations for its use in diffuse large B-cell lymphoma and in combination with polatuzumab vedotin in relapsed/refractory mantle cell lymphoma with prior BTK inhibitor therapy. Published trials show low rates of severe CRS and support outpatient administration in appropriate settings. Utilizing a search of PubMed, conference abstracts, and clinicaltrials.gov between 2020 and 2026, prospective trial data as well as retrospective real-world evidence and ongoing studies were included for a more complete picture of available data. This review summarizes the molecular design, mechanism of action, clinical efficacy, and safety of mosunetuzumab, an agent representative of immunotherapeutic advancement in lymphoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
